Survey of ophthalmology最新文献_第7页

Retinal and choroidal changes after anti-VEGF therapy in neovascular-AMD patients: A systematic review and meta-analysis of SD-OCT studies 抗血管内皮生长因子治疗后新生血管性黄斑变性患者视网膜和脉络膜的变化：SD-OCT研究的系统回顾和元分析。

IF 5.1 2区医学

Survey of ophthalmology Pub Date : 2024-04-17 DOI: 10.1016/j.survophthal.2024.04.001

Mohammad Amin Salehi , Negin Frounchi , Seyed Sina Zakavi , Soheil Mohammadi , Hamid Harandi , Shayan Shojaei , Mahdi Gouravani , J. Fernando Arevalo

{"title":"Retinal and choroidal changes after anti-VEGF therapy in neovascular-AMD patients: A systematic review and meta-analysis of SD-OCT studies","authors":"Mohammad Amin Salehi , Negin Frounchi , Seyed Sina Zakavi , Soheil Mohammadi , Hamid Harandi , Shayan Shojaei , Mahdi Gouravani , J. Fernando Arevalo","doi":"10.1016/j.survophthal.2024.04.001","DOIUrl":"10.1016/j.survophthal.2024.04.001","url":null,"abstract":"<div><h3>Background</h3><p>In recent years, the progress made in the field of optical coherence tomography has helped to understand the changes in eye layers in patients with exudative age-related macular degeneration (nAMD). Early diagnosis of nAMD, a leading cause of irreversible vision impairment, is helpful. Therefore, we performed a meta-analysis on OCT measurement alterations before and after anti-VEGF therapy in patients with nAMD and controls.</p></div><div><h3>Method</h3><p>We systematically searched Scopus, PubMed, Cochrane, and Web of Science to find articles that measured choroidal and retinal layer changes after anti-VEGF therapy in nAMD Patients. We chose either a fixed-effects or random-effects model based on the assessed heterogeneity level to perform a meta-analysis. In addition, we conducted meta-regression, subgroup analyses, publication bias, and quality assessment for included studies.</p></div><div><h3>Results</h3><p>Thirteen studies were included in the meta-analysis, with 733 total participants. Foveal thickness and subfoveal choroidal thickness (CT) decreased significantly in the first 3 years after injections, except for subfoveal CT in the third year after injection. It also showed that CT at 1500 µm temporal and nasal to the fovea did not significantly change.</p></div><div><h3>Conclusion</h3><p>Our results showed anti-VEGF treatment for nAMD patients was associated with a significant reduction in foveal thickness and subfoveal CT in the first 2 years after treatment. Our analysis did not reveal any correlation between changes in foveal thickness and subfoveal CT with best-corrected visual acuity or other factors.</p></div>","PeriodicalId":22102,"journal":{"name":"Survey of ophthalmology","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140761066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in management strategies for large and persistent macular hole: An update 持续性大黄斑孔管理策略的进展：最新进展。

IF 5.1 2区医学

Survey of ophthalmology Pub Date : 2024-03-27 DOI: 10.1016/j.survophthal.2024.03.010

Helin Arda , Mathias Maier , Maximilian Schultheiß , Christos Haritoglou

{"title":"Advances in management strategies for large and persistent macular hole: An update","authors":"Helin Arda , Mathias Maier , Maximilian Schultheiß , Christos Haritoglou","doi":"10.1016/j.survophthal.2024.03.010","DOIUrl":"10.1016/j.survophthal.2024.03.010","url":null,"abstract":"<div><p>The standard of care to treat small- and medium-sized macular holes (<400 µm diameter) consists of a conventional transconjunctival sutureless pars plana vitrectomy followed by ILM peeling and endotamponade, mainly with gas or in some cases with silicone oil, resulting in closure rates of over 90% and good functional results. Large (>400 µm diameter), chronic and persistent macular holes remain a surgical challenge since closure rates and functional results decrease with larger macular hole diameters. Various modifications of the conventional surgical technique were introduced to improve anatomic and functional success in refractory cases not suitable for conventional macular hole surgery. These techniques comprise the positioning of tissue at the top of the hole to improve closure as performed by an inner limiting membrane flap and free flap preparation or the transplantation of autologous retinal tissue, lens capsule or amniotic membrane. For the treatment of very large and persistent macular holes, the induction of a localized retinal detachment at the posterior pole by subretinal injection of balanced salt solution and a subsequent attenuation of the rim of the hole during fluid-air exchange has been suggested as a promising surgical technique. In particular, accurate patient education about the expected surgical outcome in this specific group of patients appears important.</p></div>","PeriodicalId":22102,"journal":{"name":"Survey of ophthalmology","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140327187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optical coherence tomography angiography in diabetic retinopathy: A major review 糖尿病视网膜病变的光学相干断层血管造影：主要综述。

IF 5.1 2区医学

Survey of ophthalmology Pub Date : 2024-03-22 DOI: 10.1016/j.survophthal.2024.03.004

Hosein Nouri , Seyed-Hossein Abtahi , Mehdi Mazloumi , Sanam Samadikhadem , J. Fernando Arevalo , Hamid Ahmadieh

{"title":"Optical coherence tomography angiography in diabetic retinopathy: A major review","authors":"Hosein Nouri , Seyed-Hossein Abtahi , Mehdi Mazloumi , Sanam Samadikhadem , J. Fernando Arevalo , Hamid Ahmadieh","doi":"10.1016/j.survophthal.2024.03.004","DOIUrl":"10.1016/j.survophthal.2024.03.004","url":null,"abstract":"<div><p>Diabetic retinopathy (DR) is characterized by retinal vasculopathy and is a leading cause of visual impairment. Optical coherence tomography angiography (OCTA) is an innovative imaging technology that can detect various pathologies and quantifiable changes in retinal microvasculature. We briefly describe its functional principles and advantages over fluorescein angiography and perform a comprehensive review on its clinical applications in the screening or management of people with prediabetes, diabetes without clinical retinopathy (NDR), nonproliferative DR (NPDR), proliferative DR (PDR), and diabetic macular edema (DME). OCTA reveals early microvascular alterations in prediabetic and NDR eyes, which may coexist with sub-clinical neuroretinal dysfunction. Its applications in NPDR include measuring ischemia, detecting retinal neovascularization, and timing of early treatment through predicting the risk of retinopathy worsening or development of DME. In PDR, OCTA helps characterize the flow within neovascular complexes and evaluate their progression or regression in response to treatment. In eyes with DME, OCTA perfusion parameters may be of predictive value regarding the visual and anatomical gains associated with treatment. We further discussed the limitations of OCTA and the benefits of its incorporation into an updated DR severity scale.</p></div>","PeriodicalId":22102,"journal":{"name":"Survey of ophthalmology","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140194593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IF 5.1 2区医学

Survey of ophthalmology Pub Date : 2024-03-21 DOI: 10.1016/j.survophthal.2024.03.009

Neil M. Bressler , Peter K. Kaiser , Diana V. Do , Quan Dong Nguyen , Kyu Hyung Park , Se Joon Woo , Min Sagong , Mario Bradvica , Mercy Yeeun Kim , Seungkee Kim , SriniVas R. Sadda

{"title":"Biosimilars of anti-vascular endothelial growth factor for ophthalmic diseases: A review","authors":"Neil M. Bressler , Peter K. Kaiser , Diana V. Do , Quan Dong Nguyen , Kyu Hyung Park , Se Joon Woo , Min Sagong , Mario Bradvica , Mercy Yeeun Kim , Seungkee Kim , SriniVas R. Sadda","doi":"10.1016/j.survophthal.2024.03.009","DOIUrl":"10.1016/j.survophthal.2024.03.009","url":null,"abstract":"<div><p>The development of intravitreally injected biologic medicines (biologics) acting against vascular endothelial growth factor (VEGF) substantially improved the clinical outcomes of patients with common VEGF-driven retinal diseases. The relatively high cost of branded agents, however, represents a financial burden for most healthcare systems and patients, likely resulting in impaired access to treatment and poorer clinical outcomes for some patients. Biosimilar medicines (biosimilars) are clinically equivalent, potentially economic alternatives to reference products. Biosimilars approved by leading health authorities have been demonstrated to be similar to the reference product in a comprehensive comparability exercise, generating the totality of evidence necessary to support analytical, pre-clinical, and clinical biosimilarity. Anti-VEGF biosimilars have been entering the field of ophthalmology in the US since 2022. We review regulatory and scientific concepts of biosimilars, the biosimilar development landscape in ophthalmology, with a specific focus on anti-VEGF biosimilars, and discuss opportunities and challenges facing the uptake of biosimilars.</p></div>","PeriodicalId":22102,"journal":{"name":"Survey of ophthalmology","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0039625724000298/pdfft?md5=3d98e8329dfc4dcfb85d696499bf50e5&pid=1-s2.0-S0039625724000298-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140194592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Understanding healthcare communication in age-related macular degeneration care: A mixed-methods review of patients’ perspectives 了解老年黄斑变性护理中的医疗沟通：以混合方法回顾患者的观点。

IF 5.1 2区医学

Survey of ophthalmology Pub Date : 2024-03-16 DOI: 10.1016/j.survophthal.2024.03.002

Mariska Scheffer , Juliane Menting , Hennie Boeije , Ruth van Nispen , Sandra van Dulmen

{"title":"Understanding healthcare communication in age-related macular degeneration care: A mixed-methods review of patients’ perspectives","authors":"Mariska Scheffer , Juliane Menting , Hennie Boeije , Ruth van Nispen , Sandra van Dulmen","doi":"10.1016/j.survophthal.2024.03.002","DOIUrl":"10.1016/j.survophthal.2024.03.002","url":null,"abstract":"<div><p>Age-related macular degeneration (AMD) is the most common cause of irreversible visual impairment among people aged 50 years and older. Earlier research has indicated that the communication process between patients and healthcare professionals (HCPs) leaves considerable room for improvement in AMD care. Effective communication is essential to enhance trust in the professional and understanding of the diagnosis and treatment, and decrease anxiety and stress related to illness. We review patients’ experiences, needs and preferences regarding information provision, communication style of the HCP and shared decision-making. We conducted a systematic search in PubMed, Embase, PsycINFO, CINAHL and Web of Science. Study quality was assessed using standard checklists of quality measures. Our search returned 31 eligible articles. Findings indicated current deficits in information provision for people with AMD. Patients were often ill-informed regarding the chronic character of the condition, treatment duration, nutrition, and visual aids and low vision rehabilitation. Many patients were not actively involved during the decision-making process. Altogether, patients with AMD are faced with challenges in terms of patient-HCP communication. Methods of providing information and discussing possible options for care need to be further investigated and improved for this patient group.</p></div>","PeriodicalId":22102,"journal":{"name":"Survey of ophthalmology","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0039625724000183/pdfft?md5=de4b58e9b73c0ab6eefe5c5a258f3ba9&pid=1-s2.0-S0039625724000183-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140159043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A systematic review of economic evaluation of artificial intelligence-based screening for eye diseases: From possibility to reality 基于人工智能的眼病筛查经济评估系统回顾：从可能性到现实性。

IF 5.1 2区医学

Survey of ophthalmology Pub Date : 2024-03-15 DOI: 10.1016/j.survophthal.2024.03.008

Hongkang Wu , Kai Jin , Chee Chew Yip , Victor Koh , Juan Ye

引用次数: 0

Clinical therapeutics for proliferative vitreoretinopathy in retinal detachment 视网膜脱离中增殖性玻璃体视网膜病变的临床疗法。

IF 5.1 2区医学

Survey of ophthalmology Pub Date : 2024-03-15 DOI: 10.1016/j.survophthal.2024.03.007

Francesco Sabatino , Philip Banerjee , Mahiul M. K. Muqit

{"title":"Clinical therapeutics for proliferative vitreoretinopathy in retinal detachment","authors":"Francesco Sabatino , Philip Banerjee , Mahiul M. K. Muqit","doi":"10.1016/j.survophthal.2024.03.007","DOIUrl":"10.1016/j.survophthal.2024.03.007","url":null,"abstract":"<div><p>Proliferative vitreoretinopathy (PVR) is an abnormal and prolonged healing response to retinal injury (retinal detachment, post retinal detachment surgery) characterised by: pre/subretinal membrane formation; retinal gliosis and retinal shortening, retinal pigment epithelium cell proliferation; and increased glial (mainly Mu¨ller cells), fibroblast and inflammatory cell (macrophage, lymphocyte) activity, leading to tractional retinal holes/breaks and multiple costly eye operations suffered by patients. PVR can cause retinal re-detachment following primary surgical intervention for rhegmatogenous retinal detachment. Vitrectomy and scleral buckling surgery are the main approaches for treating PVR complications of retinal detachment. Patients require many operations to remove the scar tissue but vision results are suboptimal, and do not meet patient expectations. Over the past 40 years, this has been one of the greatest challenges for vitreoretinal surgeons and patients. Despite previous large clinical trials of multiple candidate drug therapeutics, no proven adjunctive treatment currently exists to either prevent, reduce, or treat PVR formation in retinal detachment. Both cellular proliferation and the intraocular inflammatory response are realistic targets for adjunctive treatments in PVR. The cellular components of PVR periretinal membranes (retinal pigment epithelial, glial, inflammatory and fibroblastic cells) proliferate and are thus targets for antiproliferative agents. In recent years, several new therapeutics have been tested, and we present an updated review of the clinical therapeutics for PVR in retinal detachment.</p></div>","PeriodicalId":22102,"journal":{"name":"Survey of ophthalmology","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140140855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current management options for the treatment of refractory postoperative cystoid macular edema: A systematic review 目前治疗难治性术后囊样黄斑水肿的方法：系统综述。

IF 5.1 2区医学

Survey of ophthalmology Pub Date : 2024-03-14 DOI: 10.1016/j.survophthal.2024.03.005

Layla J. Bunjo , Stephen Bacchi , James Pietris , Weng Onn Chan

引用次数: 0

Clinical outcome measures in vision and eye care 视力和眼科护理的临床结果测量。

IF 5.1 2区医学

Survey of ophthalmology Pub Date : 2024-03-13 DOI: 10.1016/j.survophthal.2024.03.006

Luke Leidy , Anna Dickinson , Pradeep Ramulu , Joshua Ehrlich , Mona A. Kaleem

引用次数: 0

Medication-associated orbital inflammation: A systematic review 药物相关眼眶炎症：系统综述。

IF 5.1 2区医学

Survey of ophthalmology Pub Date : 2024-03-13 DOI: 10.1016/j.survophthal.2024.03.003

Terence Ang MBBS , Viraj Chaggar , Jessica Y. Tong FRANZCO , Dinesh Selva DHSc FRANZCO FRACS

{"title":"Medication-associated orbital inflammation: A systematic review","authors":"Terence Ang MBBS , Viraj Chaggar , Jessica Y. Tong FRANZCO , Dinesh Selva DHSc FRANZCO FRACS","doi":"10.1016/j.survophthal.2024.03.003","DOIUrl":"10.1016/j.survophthal.2024.03.003","url":null,"abstract":"<div><p>We performed a comprehensive systematic review to identify medication-associated orbital inflammation and to characterize its clinico-radiological features. We reviewed English-language articles describing medication-associated orbital inflammation (i.e., orbital myositis, dacryoadenitis and orbital fat) published to June, 2023. Isolated inflammation of the intraocular structures or globe alone (i.e. uveitis, scleritis, optic neuritis and perineuritis) were excluded. In medication-associated orbital inflammation, the extraocular muscles are preferentially affected, occurring in isolation or in combination with other orbital and/or intraocular structures. Clinico-radiological manifestations may be non-specific; however, certain medications may be distinguished according to the presence of systemic prodrome, laterality, associated intraocular inflammation, and predisposition to involve certain orbital structures. Rapid identification, discontinuation of the provoking medication, and systemic corticosteroid therapy (if appropriate) typically achieves a favorable visual prognosis. As new medications become adopted by clinicians, rare adverse effects will be further delineated.Medication-associated orbital inflammation is an important diagnostic consideration in orbital inflammatory disease. A careful medication history and clinical assessment may be revealing, permitting timely discontinuation of the offending agent and initiation of appropriate management.</p></div>","PeriodicalId":22102,"journal":{"name":"Survey of ophthalmology","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0039625724000201/pdfft?md5=fa20309de7d4dc0ecb51ae16a8b32310&pid=1-s2.0-S0039625724000201-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140137306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0